Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 13/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | MAP2K1 | Q02750 | 2/20 | 0.38 |
| ▸ | LCK | P06239 | 1/20 | 0.38 |
| ▸ | KIT | P10721 | 1/20 | 0.38 |
| ▸ | KDR | P35968 | 1/20 | 0.38 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3671793 | 0.80 | MAPK14 (0.42) | MAPK14CYP3A4LCKKITKDR | |
| SCHEMBL3666224 | 0.74 | MAPK14 (0.81) | MAPK14CYP3A4LCKKITKDR | |
| SCHEMBL3770447 | 0.67 | TP53 (0.40) | MAPK14CYP3A4LCKKITKDR | |
| SCHEMBL1883322 | 0.67 | MAPK14 (0.44) | MAPK14CYP3A4LCKKITKDR | |
| SCHEMBL1878339 | 0.64 | MAPK14 (0.46) | MAPK14CYP3A4LCKKITKDR | |
| SCHEMBL30568558 | 0.63 | CYP11B2 (0.40) | MAPK14GAA | |
| SCHEMBL29703261 | 0.63 | NPC1 (0.54) | L3MBTL1 | |
| SCHEMBL1877849 | 0.62 | MAPK14 (0.47) | MAPK14CYP3A4LCKKITKDR | |
| SCHEMBL14966292 | 0.61 | CYP17A1 (0.41) | MAPK14CYP3A4LCKKITKDR | |
| SCHEMBL9665772 | 0.60 | RAB9A (0.50) | MAPK14CYP3A4L3MBTL1CYP2C19GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7846944-B2 | Pyrazolo-pyridinone compounds and methods of use thereof | AMGEN INC. (US) | 2010-12-07 | — | — | US | disclosed |
| EP-2152704-A1 | PYRAZOLO-PYRIDINONE COMPOUNDS, PROCESS FOR THEIR PREPARATION, AND THEIR PHARMACEUTICAL USE | Amgen, Inc (US) | 2010-02-17 | — | — | EP | disclosed |
| US-20090012299-A1 | Pyrazolo-pyridinone compounds and methods of use thereof | AMGEN INC. (US) | 2009-01-08 | — | — | US | disclosed |
| WO-2008137176-A1 | PYRAZOLO-PYRIDINONE COMPOUNDS, PROCESS FOR THEIR PREPARATION, AND THEIR PHARMACEUTICAL USE | AMGEN INC. (US) | 2008-11-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090012299-A1 | Pyrazolo-pyridinone compounds and methods of use thereof | MAPK1, MAP3K1, MAP4K2 | MAPK14 41/4885CYP3A4 964/4885MAP2K1 117/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.